Drug intelligence / Profile preview

FT596

Development stage: Discontinued
Lead developer: Fate Therapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

FT596 is an investigational, universal, off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line. It is engineered with three active anti-tumor components: a chimeric antigen receptor (CAR) targeting CD19; a high-affinity non-cleavable CD16 Fc receptor to enhance antibody-dependent cellular cytotoxicity and enable combination with monoclonal antibodies such as rituximab (targeting CD20); and an IL-15/IL-15 receptor fusion to promote NK cell survival and proliferation without systemic cytokine support. This multi-antigen targeting approach aims to overcome resistance due to antigen escape in B-cell malignancies. FT596 is designed for scalable, standardized manufacturing and off-the-shelf use in patients with relapsed or refractory B-cell lymphoma and leukemia[1][3][5][6][8].

Other names: iPSC-derived CD16/IL-15RF-expressing anti-CD19 CAR-NK cells

Targets

IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)CD19 (B lymphocyte antigen CD19)IgG1 Fc (Immunoglobulin G1 Fc region)

Beyond the preview

Go deeper on FT596.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FT596.

Explore the full profile